BRPI0909910A2 - "método de tratamento, inibição ou redução da probabilidade de lúpus eritematoso sistêmico (les) ou de um estado de doença secundária, condição ou manifestação associada ao lúpus eritematoso sistêmico ou à púrpura trombocitopênica imunológica em um paciente, composição farmacêutica e seu uso" - Google Patents

"método de tratamento, inibição ou redução da probabilidade de lúpus eritematoso sistêmico (les) ou de um estado de doença secundária, condição ou manifestação associada ao lúpus eritematoso sistêmico ou à púrpura trombocitopênica imunológica em um paciente, composição farmacêutica e seu uso"

Info

Publication number: BRPI0909910A2
Authority: BR; Brazil
Prior art keywords: lupus erythematosus; systemic lupus; les; likelihood; inhibiting
Prior art date: 2008-06-03

Application number

BRPI0909910A

Other languages

English (en)

Inventor

Clos Terry W Du

Mold Carolyn

Original Assignee

Stc Unm

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-06-03

Filing date

2009-06-02

Publication date

2016-10-11

2009-06-02 Application filed by Stc Unm filed Critical Stc Unm

2016-10-11 Publication of BRPI0909910A2 publication Critical patent/BRPI0909910A2/pt

Links

201000000596 systemic lupus erythematosus Diseases 0.000 title 2
208000028622 Immune thrombocytopenia Diseases 0.000 title 1
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
208000037921 secondary disease Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1745—C-reactive proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4737—C-reactive protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Nutrition Science (AREA)
Genetics & Genomics (AREA)
Hospice & Palliative Care (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Otolaryngology (AREA)
Toxicology (AREA)
Cardiology (AREA)
Marine Sciences & Fisheries (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)

BRPI0909910A 2008-06-03 2009-06-02 "método de tratamento, inibição ou redução da probabilidade de lúpus eritematoso sistêmico (les) ou de um estado de doença secundária, condição ou manifestação associada ao lúpus eritematoso sistêmico ou à púrpura trombocitopênica imunológica em um paciente, composição farmacêutica e seu uso" BRPI0909910A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13074908P	2008-06-03	2008-06-03
PCT/US2009/003338 WO2009148566A2 (en)	2008-06-03	2009-06-02	Development of a c-reactive protein mutant with improved therapeutic benefit in immune thrombocytopenia and lupus nephritis

Publications (1)

Publication Number	Publication Date
BRPI0909910A2 true BRPI0909910A2 (pt)	2016-10-11

Family

ID=41398720

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0909910A BRPI0909910A2 (pt)	2008-06-03	2009-06-02	"método de tratamento, inibição ou redução da probabilidade de lúpus eritematoso sistêmico (les) ou de um estado de doença secundária, condição ou manifestação associada ao lúpus eritematoso sistêmico ou à púrpura trombocitopênica imunológica em um paciente, composição farmacêutica e seu uso"

Country Status (5)

Country	Link
US (1)	US20130072445A9 (pt)
EP (1)	EP2303306A4 (pt)
JP (1)	JP2011522044A (pt)
BR (1)	BRPI0909910A2 (pt)
WO (1)	WO2009148566A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5959440B2 (ja)	2010-01-19	2016-08-02	プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ	病原体の検出および治療のための改変オプソニン
AU2012284097B2 (en)	2011-07-18	2017-08-03	President And Fellows Of Harvard College	Engineered microbe-targeting molecules and uses thereof
WO2014144325A1 (en)	2013-03-15	2014-09-18	President And Fellows Of Harvard College	Methods and compositions for improving detection and/or capture of a target entity
WO2014190040A1 (en)	2013-05-21	2014-11-27	President And Fellows Of Harvard College	Engineered heme-binding compositions and uses thereof
EP3083658B1 (en)	2013-12-18	2019-05-08	President and Fellows of Harvard College	Crp capture/detection of gram positive bacteria
EP3763378A1 (en)	2015-08-06	2021-01-13	President and Fellows of Harvard College	Improved microbe-binding molecules and uses thereof
CN114302761A (zh) *	2019-05-09	2022-04-08	特鲁维安科学公司	逆转血小板聚集的方法和组合物
USD1116151S1 (en)	2023-05-03	2026-03-03	Truvian Sciences, Inc.	Monolayer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5547931A (en) *	1994-02-23	1996-08-20	Immtech International Inc.	Methods of stimulatory thrombocytopoiesis using modified C-reactive protein
WO2005056044A1 (en) *	2003-10-23	2005-06-23	Terry Du Clos	Use of c-reactive protein to treat immune complex-mediated renal disease
US8013120B2 (en) *	2005-10-26	2011-09-06	Stc.Unm	C-reactive protein and its use to treat systemic lupus erythematosus and related conditions
CA2670125A1 (en) *	2006-11-06	2008-05-15	Stc.Unm	Suppressive macrophages, c-reactive protein and the treatment of systemic lupus erythematosus and immune thrombocytopenic purpura

2009
- 2009-06-02 US US12/995,828 patent/US20130072445A9/en not_active Abandoned
- 2009-06-02 EP EP09758730A patent/EP2303306A4/en not_active Withdrawn
- 2009-06-02 BR BRPI0909910A patent/BRPI0909910A2/pt not_active IP Right Cessation
- 2009-06-02 WO PCT/US2009/003338 patent/WO2009148566A2/en not_active Ceased
- 2009-06-02 JP JP2011512464A patent/JP2011522044A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
WO2009148566A3 (en)	2010-02-25
JP2011522044A (ja)	2011-07-28
EP2303306A4 (en)	2012-08-22
WO2009148566A2 (en)	2009-12-10
US20130072445A9 (en)	2013-03-21
EP2303306A2 (en)	2011-04-06
US20110152202A1 (en)	2011-06-23

Similar Documents

Publication	Publication Date	Title
BRPI0909910A2 (pt)	2016-10-11	"método de tratamento, inibição ou redução da probabilidade de lúpus eritematoso sistêmico (les) ou de um estado de doença secundária, condição ou manifestação associada ao lúpus eritematoso sistêmico ou à púrpura trombocitopênica imunológica em um paciente, composição farmacêutica e seu uso"
BRPI1011760A2 (pt)	2015-10-06	método para prevenir ou reduzir coagulação no trato gastrointestinal superior de um indivíduo, e, uso de proteína anticoagulante.
BR112017024928A2 (pt)	2018-07-31	Métodos para prevenção da diabetes ou pré- diabetes em um indivíduo, para melhoria da resposta à glicose em um indivíduo com intolerância à glicose, para manutenção da resposta à glicose em um indivíduo com tolerância à glicose e para melhoria da saúde de um indivíduo, composição probiótica e composição farmacêutica
BRPI1009381A2 (pt)	2016-06-21	compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica
BR112013000842A2 (pt)	2016-06-07	composições farmacêuticas, método de tratamento de condição de etiologia funcional do trato gastrointestinal e uso de forma potenciada ativada de anticorpo para a proteína s-100, de forma potenciada ativada de anticorpo para histamina e de forma potenciada ativada de anticorpo para a tnf-alfa.
EP2650002A4 (en)	2014-08-13	BIFIDOBACTERIUM CECT 7765 AND ITS USE IN THE PREVENTION AND / OR TREATMENT OF OVERWEIGHT, ADIPOSITAS AND SIMILAR ILLNESS
IL246181A0 (en)	2016-07-31	Methods of producing retinal pigment epithelium (rpe) cells, compositions comprising the same, and uses thereof in the preparation of medicaments for treating or preventing a condition characterized by retinal degeneration
IL219876A (en)	2016-02-29	Antibodies against human 1h-7b or its fragment, preparations containing them and their use in the preparation of drugs
EP2349401A4 (en)	2013-10-02	ONE-WAY INFUSION DEVICE WITH REDUNDANT VALVE SAFETY
ATE551077T1 (de)	2012-04-15	Minderung einer infektion in zusammenhang mit einer medizinischen vorrichtung
IL215603A0 (en)	2011-12-29	Human protein scaffold with controlled serum pharmacokinetics, compositions comprising the same and uses thereof
MX2021004308A (es)	2022-10-26	Empagliflozina para usarse en el tratamiento de micro y macroalbuminuria.
IL207439B (en)	2019-01-31	Use of an antagonistic antibody against calcitonin gene-related peptide (cgrp) for the preparation of a drug for the prevention and/or treatment of joint pain
CL2007001847A1 (es)	2008-02-08	Composicion farmaceutica intramuscular o subcutanea que comprende tmc278 (rilpivirina); proceso para preparar la composicion; y uso para el tratamiento o prevencion de infeccion por vih.
BRPI0922435A2 (pt)	2018-09-11	"composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
BRPI0811262A2 (pt)	2014-11-04	Composto, composto ou sal do mesmo, composição farmacêutica, modulador de receptor de glicocorticóide, método para prevenção e/ou tratamento de bistúrbios metabólicos, doenças inflamatórias, doenças auto-imunes, doenças alérgicas, doenças do sistema nervoso central, doenças cardiovasculares, doenças relacionadas com homeostase ou glaucoma, e uso de pelo menos um composto ou um sal do mesmo
BRPI0718307A2 (pt)	2014-04-29	Uso de oligossacarídeos indigeríveis, composição nutricional, oligossacarídeos indigeríveis, e, método para melhora de resistência à insulina, prevenção da queda glicêmica pós-prandial e/ou diminuição da resposta à glicose pós-prandial de uma refeição
WO2010045407A3 (en)	2011-01-20	Reduction of infection associated with medical device
BRPI0817905A2 (pt)	2014-10-07	Utilização de uma cepa de bifidobacterium, para o preparo de uma composição destinada à prevenção e/ou ao tratamento de manifestações do tipo alérgicas
BR112013014189A2 (pt)	2017-08-01	composição farmacêutica que compreende transcinamaldeíco e o uso da mesma no tratamento de infecções
IL215483A (en)	2017-07-31	6,4,2-Triple fluoro-n- [6- (1-methyl-piperidine-4-carbonyl) -pyrimidine-2-yl] -benzamide and its use in the preparation of a drug to treat or prevent migraines
WO2009068708A3 (es)	2009-07-16	Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo
EP3378415A4 (en)	2019-10-09	IN VIVO RESIDENTIAL ELEMENT AND POSITIONING DEVICE FOR IN VIVO RESIDENTIAL ELEMENTS WITH THIS IN VIVO RESIDENTIAL ELEMENT
WO2009046015A3 (en)	2009-07-16	Combination therapies for treating type 1 diabetes
PL1921210T3 (pl)	2015-10-30	Element zabezpieczający przed lawiną i tym podobnymi

Legal Events

Date	Code	Title	Description
2016-10-18	B15I	Others concerning applications: loss of priority	Free format text: OBSERVA-SE QUE A PRIORIDADE REQUERIDA US 61/130,749 DE 03.06.2008 POSSUI DEPOSITANTE DIFERENTE DO INFORMADO NA ENTRADA NA FASE NACIONAL E SUA RESPECTIVA CESSAO NAO FOI APRESENTADA, MOTIVO PELO QUAL SERA DADA PERDA DESTA PRIORIDADE, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O.
2017-02-07	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2017-05-30	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
2021-06-08	B350	Update of information on the portal [chapter 15.35 patent gazette]